RJA
CALA

Raymond James & Associates’s Calithera Biosciences, Inc CALA Stock Holding History

Raymond James & Associates’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-600
Closed -$59K – 4146
2020
Q4 		$59K Buy
+600
New +$52.6K ﹤0.01% 3610

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's CALA Position: Q1 2021 in Review

Raymond James & Associates sold out of Calithera Biosciences, Inc (CALA) in Q1 2021, closing a stake of 600 shares — an estimated $59K sold.

Raymond James & Associates first reported a position in CALA in Q4 2020 and held it in 1 quarter. The position peaked at $59K in Q4 2020. 100 funds tracked by Wall St. Rank hold CALA as of Q1 2021.

  • Raymond James & Associates reported no remaining Calithera Biosciences, Inc position as of Q1 2021 after selling out during the quarter.
  • Raymond James & Associates sold 600 Calithera Biosciences, Inc shares in Q1 2021, an estimated $59K.
  • Raymond James & Associates first reported a position in Calithera Biosciences, Inc in Q4 2020 and held it in 1 quarter.
  • Raymond James & Associates's Calithera Biosciences, Inc position peaked at $59K in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2021.

Based on Raymond James & Associates's 13F filing for Q1 2021, filed 14 May 2021.